Author

B. Whitener

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 6 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Research Focus:host-pathogen & immune response· 7 Research Focus:drug response / drug discovery· 5 Organism:mouse· 5 Organism:human· 3 Assay:proteomics· 3 Approach:statistical model· 2 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

B. Ying· 5 shared D. K. Edwards· 5 shared L. B. Thackray· 5 shared M. S. Diamond· 5 shared A. Carfi· 4 shared J. B. Case· 4 shared S. M. Scheaffer· 4 shared C.-Y. Liang· 3 shared

Activity by Year

2021-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

B. Ying

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants

T. A. Desautels, K. T. Arrildt, A. T. Zemla, E. Y. Lau, F. Zhu, D. Ricci, S. Cronin, S. Zost, E. Binshtein, S. M. Scheaffer, B. Dadonaite, B. K. Petersen, T. B. Engdahl, E. Chen, L. S. Handal, , Carnahan

This paper computationally redesigns an antibody to restore potency against SARS-CoV-2 Omicron subvariants while maintaining efficacy against Delta and other variants.

Nature · May 8, 2024Peer-reviewedMicrobiology

Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants

A. Addetia, L. Piccoli, J. B. Case, Y.-J. Park, M. Beltramello, B. Guarino, H. Dang, D. Pinto, S. Scheaffer, K. Sprouse, J. Bassi, C. Silacci-Fregni, F. Muoio, M. Dini, L. Vincenzetti, , Fran

The paper shows that cross-reactive antibodies, like S309, retain effector functions against emerging Omicron variants despite reduced neutralization.

bioRxiv · Jan 17, 2023 · PreprintImmunology

Development of SARS-CoV-2 mRNA vaccines encoding spike N-terminal and receptor binding domains

G. Stewart-Jones, S. M. Elbashir, K. Wu, D. Lee, I. Renzi, B. Ying, M. Koch, C. E. Sein, A. Choi, B. Whitener, D. Garcia-Dominguez, C. Henry, A. Woods, L. Ma, D. Montes Berrueta, , A. Carfi

The paper develops and evaluates an mRNA vaccine, mRNA-1283, encoding SARS-CoV-2 spike N-terminal and receptor-binding domains, showing improved immunogenicity and protection against multiple variants in mice.

bioRxiv · Oct 7, 2022 · PreprintImmunology

Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant

S. M. Scheaffer, D. Lee, B. Whitener, B. Ying, K. Wu, H. Jani, P. Martin, N. J. Amato, L. E. Avena, D. M. Berrueta, S. D. Schmidt, S. O'Dell, A. Nasir, G.-Y. Chuang, G. Stewart-Jones, , M. S. Diamond

This study evaluates bivalent SARS-CoV-2 mRNA vaccines and finds they induce broader neutralizing antibodies and better protection against BA.5 Omicron compared to monovalent vaccines.

bioRxiv · Sep 12, 2022 · PreprintMicrobiology

Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice

B. Ying, S. M. Scheaffer, B. Whitener, C.-Y. Liang, O. Dmytrenko, S. Mackin, K. Wu, D. Lee, L. E. Avena, Z. Chong, J. B. Case, L. Ma, T. Kim, C. Sein, A. Woods, , M. S. Diamond

This study shows that boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibodies and protection against B.1.1.529 in mice, with the Omicron-matched booster showing slightly better outcomes.

bioRxiv · Feb 7, 2022 · PreprintMicrobiology

mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2

T. L. Darling, B. Ying, B. Whitener, L. VanBlargan, T. L. Bricker, C.-Y. Liang, A. Joshi, G. Bamunuarachchi, K. Seehra, A. Schmitz, P. Halfmann, Y. Kawaoka, S. Elbashir, D. K. Edwards, L. Thackray, , A. Boon

This study evaluates the efficacy of mRNA-1273 and Ad26.COV2.S vaccines against the B.1.621 variant in mice and hamsters, showing protection against infection and pathology.

bioRxiv · Dec 29, 2021Microbiology

Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains

B. Ying, B. Whitener, L. A. VanBlargan, A. O. Hassan, S. Shrihari, C.-Y. Liang, C. E. Karl, S. Mackin, R. E. Chen, N. M. Kafai, S. H. Wilks, D. J. Smith, J. M. Carreno, G. Singh, F. Krammer, , M. S. Diamond

This study evaluates the protective efficacy of mRNA vaccines against SARS-CoV-2 variants in mice, showing that low-dose vaccines lead to breakthrough infections with Delta variant.

bioRxiv · Aug 25, 2021Microbiology

A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope

L. VanBlargan, L. Adams, Z. Liu, R. E. Chen, P. Gilchuk, S. Raju, B. Smith, H. Zhao, J. B. Case, E. S. Winkler, B. Whitener, L. Droit, I. Aziati, P.-Y. Shi, A. Creanga, , M. Diamond

The paper identifies an antibody that neutralizes all SARS-CoV-2 variants by targeting a conserved epitope on the spike protein.

bioRxiv · Apr 26, 2021Microbiology